ODE III deputy director appointed
Executive Summary
Office of Drug Evaluation III Deputy Director Julie Beitz, MD, brings experience coordinating drug risk management programs to new post, effective March 23. Beitz was director of FDA's Division of Drug Risk Evaluation within the Office of Drug Safety since February 2000, and first joined FDA in 1994 as a medical officer in the Division of Oncology & Pulmonary Drug Products...
You may also be interested in...
FDA Office Of Drug Safety Gets Two Permanent Division Directors
Two of the three divisions in FDA's Office of Drug Safety now have permanent directors
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.